GNPX - Genprex (GNPX) - Reqorsa Could Be The First Systemic Gene Therapy
Genprex Has Developed a Proprietary System For Gene Delivery. The Oncoprex technology uses nanoparticles to deliver genes using intravenous administration rather than a viral vector delivered directly to the tumor site. The company's first product, Reqorsa, uses the Oncoprex system to deliver a tumor suppressor gene. Reqorsa began a Phase 1/2 clinical trial in non-small cell lung cancer (NSCLC) and is expect to being a Phase 1/2 immunotherapy combination trial in early 2022.Gene Therapy With A Tumor Suppressor Reqorsa was developed to deliver TUSC2 gene, a tumor suppressor gene. TUSC2 has been shown to stop pathways of cancer cell proliferation and start pathways that lead to cell death (apoptosis). These pathways may be additive or synergistic with actions of other drugs that act through intracellular signaling.The ACCLAIM-1 Trial Tests Reqorsa In NSCLC The ACCLAIM-1 is a Phase 1/2 clinical trial testing Reqorsa in non small cell lung cancer (NSCLC) administered in combination with the EGF inhibitor Tagrisso and standard-of-care chemotherapy. Genprex has received Fast Track from the FDA for this combination in NSCLC.ACCLAIM-2 Tests Reqorsa in Immunotherapy Reqorsa has been shown to increase the immune system response to tumors and reduce expression of PD-L1, a surface market that allows cancer cells to avoid being killed by the immune systems. These two mechanisms may improve the response to checkpoint inhibitors. The ACCLAIM-2 trial has been designed to test Reqorsa in combination with the checkpoint inhibitor Keytruda (pembrolizumab) in NSCLC.Conclusion: We expect GNPX to be driven by the start of the ACCLAIM-2 trial, enrollment milestones from ACCLAIM-1, and the interim analysis from ACCLAIM-1. We believe these upcoming milestones could raise awareness of its potential, and positive data consistent with the earlier study would increase its valuation. Based on market valuations of comparable companies, we base our price target on a market capitalization of of $175 million or $3.50 per share. Read More >>